Oral Mucositis-Pipeline Review, H1 2016

Oral Mucositis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7743IDB
  • |
  • Pages: 95
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Oral Mucositis-Pipeline Review, H1 2016', provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Oral Mucositis

The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects

The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Oral Mucositis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Oral Mucositis Overview 8

Therapeutics Development 9

Pipeline Products for Oral Mucositis-Overview 9

Pipeline Products for Oral Mucositis-Comparative Analysis 10

Oral Mucositis-Therapeutics under Development by Companies 11

Oral Mucositis-Therapeutics under Investigation by Universities/Institutes 12

Oral Mucositis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Oral Mucositis-Products under Development by Companies 16

Oral Mucositis-Products under Investigation by Universities/Institutes 17

Oral Mucositis-Companies Involved in Therapeutics Development 18

Aldeyra Therapeutics, Inc. 18

Cellceutix Corporation 19

Colby Pharmaceutical Company 20

Daewoong Pharmaceutical Co., Ltd. 21

Galera Therapeutics, Inc. 22

Intrexon Corporation 23

Onxeo SA 24

Otsuka Holdings Co., Ltd. 25

ProCertus BioPharm Inc. 26

Soligenix, Inc. 27

Spectrum Pharmaceuticals, Inc. 28

Spherium Biomed S.L. 29

Sucampo Pharmaceuticals, Inc. 30

Oral Mucositis-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

AG-013-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

brilacidin tetrahydrochloride-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

clonidine hydrochloride ER-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

cobiprostone-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

dusquetide-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

GC-4419-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Gene Therapy for Oral Mucositis-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Gene Therapy for Oral Mucositis-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

KIN-219-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

nepidermin-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

NS-2-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

OralX-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

pralatrexate-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

rebamipide-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

SP-13004-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Oral Mucositis-Recent Pipeline Updates 62

Oral Mucositis-Dormant Projects 83

Oral Mucositis-Discontinued Products 86

Oral Mucositis-Product Development Milestones 87

Featured News & Press Releases 87

Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis 87

Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis 87

Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 88

Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015 89

Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis 89

Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis 90

Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 91

Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting 91

Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 92

Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis 92

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

List of Figures

Number of Products under Development for Oral Mucositis, H1 2016 9

Number of Products under Development for Oral Mucositis-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 31

Number of Products by Top 10 Targets, H1 2016 32

Number of Products by Stage and Top 10 Targets, H1 2016 32

Number of Products by Top 10 Mechanism of Actions, H1 2016 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 34

Number of Products by Routes of Administration, H1 2016 36

Number of Products by Stage and Routes of Administration, H1 2016 36

Number of Products by Molecule Types, H1 2016 38

Number of Products by Stage and Molecule Types, H1 2016 38

List of Tables

Number of Products under Development for Oral Mucositis, H1 2016 9

Number of Products under Development for Oral Mucositis-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Oral Mucositis-Pipeline by Aldeyra Therapeutics, Inc., H1 2016 18

Oral Mucositis-Pipeline by Cellceutix Corporation, H1 2016 19

Oral Mucositis-Pipeline by Colby Pharmaceutical Company, H1 2016 20

Oral Mucositis-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 21

Oral Mucositis-Pipeline by Galera Therapeutics, Inc., H1 2016 22

Oral Mucositis-Pipeline by Intrexon Corporation, H1 2016 23

Oral Mucositis-Pipeline by Onxeo SA, H1 2016 24

Oral Mucositis-Pipeline by Otsuka Holdings Co., Ltd., H1 2016 25

Oral Mucositis-Pipeline by ProCertus BioPharm Inc., H1 2016 26

Oral Mucositis-Pipeline by Soligenix, Inc., H1 2016 27

Oral Mucositis-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 28

Oral Mucositis-Pipeline by Spherium Biomed S.L., H1 2016 29

Oral Mucositis-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 30

Assessment by Monotherapy Products, H1 2016 31

Number of Products by Stage and Target, H1 2016 33

Number of Products by Stage and Mechanism of Action, H1 2016 35

Number of Products by Stage and Route of Administration, H1 2016 37

Number of Products by Stage and Molecule Type, H1 2016 39

Oral Mucositis Therapeutics-Recent Pipeline Updates, H1 2016 62

Oral Mucositis-Dormant Projects, H1 2016 83

Oral Mucositis-Dormant Projects (Contd..1), H1 2016 84

Oral Mucositis-Dormant Projects (Contd..2), H1 2016 85

Oral Mucositis-Discontinued Products, H1 2016 86

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aldeyra Therapeutics, Inc.

Cellceutix Corporation

Colby Pharmaceutical Company

Daewoong Pharmaceutical Co., Ltd.

Galera Therapeutics, Inc.

Intrexon Corporation

Onxeo SA

Otsuka Holdings Co., Ltd.

ProCertus BioPharm Inc.

Soligenix, Inc.

Spectrum Pharmaceuticals, Inc.

Spherium Biomed S.L.

Sucampo Pharmaceuticals, Inc.

Oral Mucositis Therapeutic Products under Development, Key Players in Oral Mucositis Therapeutics, Oral Mucositis Pipeline Overview, Oral Mucositis Pipeline, Oral Mucositis Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com